Literature DB >> 24768478

Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.

Anneleen Reynders1, Olivier Brouckaert1, Ann Smeets1, Annouschka Laenen1, Emi Yoshihara1, Frederik Persyn1, Giuseppe Floris2, Karin Leunen1, Frederic Amant1, Julie Soens3, Chantal Van Ongeval3, Philippe Moerman2, Ignace Vergote1, Marie-Rose Christiaens1, Gracienne Staelens4, Koen Van Eygen4, Alain Vanneste5, Peter Van Dam6, Cecile Colpaert7, Patrick Neven8.   

Abstract

Completion axillary lymph node dissection (cALND) is the golden standard if breast cancer involves the sentinel lymph node (SLN). However, most non-sentinel lymph nodes (NSLN) are not involved, cALND has a considerable complication rate and does not improve outcome. We here present and validate our predictive model for positive NSLNs in the cALND if the SLN is positive. Consecutive early breast cancer patients from one center undergoing cALND for a positive SLN were included. We assessed demographic and clinicopathological variables for NSLN involvement. Uni- and multivariate analysis was performed. A predictive model was built and validated in two external centers. 21.9% of 470 patients had at least one involved NSLN. In univariate analysis, seven variables were significantly correlated with NSLN involvement: tumor size, grade, lymphovascular invasion (LVI), number of positive and negative SLNs, size of SLN metastasis and intraoperative positive SLN. In multivariate analysis, LVI, number of negative SLNs, size of SLN metastasis and intraoperative positive pathological evaluation were independent predictors for NSLN involvement. The calculated risk resulted in an AUC of 0.76. Applied to the external data, the model was accurate and discriminating for one (AUC = 0.75) and less for the other center (AUC = 0.58). A discriminative predictive model was constructed to calculate the risk of NSLN involvement in case of a positive SLN. External validation of our model reveals differences in performance when applied to data from other institutions concluding that such a predictive model requires validation prior to use.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; External validation; Non-sentinel lymph node involvement; Prediction; Sentinel lymph node

Mesh:

Year:  2014        PMID: 24768478     DOI: 10.1016/j.breast.2014.03.009

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  5 in total

1.  Peritumoral apparent diffusion coefficients for prediction of lymphovascular invasion in clinically node-negative invasive breast cancer.

Authors:  Naoko Mori; Shunji Mugikura; Chiaki Takasawa; Minoru Miyashita; Akiko Shimauchi; Hideki Ota; Takanori Ishida; Atsuko kasajima; Kei Takase; Tetsuya Kodama; Shoki Takahashi
Journal:  Eur Radiol       Date:  2015-05-30       Impact factor: 5.315

2.  CK19 mRNA in blood can predict non-sentinel lymph node metastasis in breast cancer.

Authors:  Xing-Fei Yu; Hong-Jian Yang; Lei Lei; Chen Wang; Jian Huang
Journal:  Oncotarget       Date:  2016-05-24

3.  A Predictive Model for Nonsentinel Node Status after Sentinel Lymph Node Biopsy in Sentinel Lymph Node-Positive Chinese Women with Early Breast Cancer.

Authors:  Lifang He; Peide Liang; Huancheng Zeng; Guangsheng Huang; Jundong Wu; Yiwen Zhang; Yukun Cui; Wenhe Huang
Journal:  J Oncol       Date:  2022-02-24       Impact factor: 4.375

4.  Imaging Predictors for Nonsentinel Lymph Node Metastases in Breast Cancer Patients.

Authors:  Yizi Cong; Suxia Wang; Haidong Zou; Shiguang Zhu; Xingmiao Wang; Jianqiao Cao; Ji Wang; Yanqing Liu; Guangdong Qiao
Journal:  Breast Care (Basel)       Date:  2019-10-29       Impact factor: 2.860

5.  Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study.

Authors:  Carlos López; Ramón Bosch-Príncep; Guifré Orero; Laia Fontoura Balagueró; Anna Korzynska; Marcial García-Rojo; Gloria Bueno; Maria Del Milagro Fernández-Carrobles; Lukasz Roszkowiak; Cristina Callau Casanova; M Teresa Salvadó-Usach; Joaquín Jaén Martínez; Albert Gibert-Ramos; Albert Roso-Llorach; Andrea Gras Navarro; Marta Berenguer-Poblet; Montse Llobera; Júlia Gil Garcia; Bárbara Tomás; Vanessa Gestí; Eeva Laine; Benoít Plancoulaine; Jordi Baucells; Maryléne Lejeune
Journal:  PeerJ       Date:  2020-09-02       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.